Genetics of Rheumatoid Arthritis
Launched by NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES (NIAMS) · Nov 3, 1999
Trial Information
Current as of March 19, 2025
Completed
Keywords
ClinConnect Summary
The purpose of this protocol is to identify genetic susceptibility loci for rheumatoid arthritis. The Genetics and Genomics Branch of the Intramural Research Program of NIAMS \[now the
Inflammatory Diseases Section of the Intramural Research Program of NHGRI\] has joined with
several extramural centers to form the North American Rheumatoid Arthritis Consortium
(NARAC). The Consortium intends to identify and obtain clinical specimens on a total of 1000
sibling pairs with rheumatoid arthritis; up to 100 sibling pairs will be recruited at the Clinical
Center. Samples from parents and othe...
Gender
ALL
Eligibility criteria
- * INCLUSION CRITERIA:
- SIBLING PAIR:
- • A diagnosis of rheumatoid arthritis in both sibs by the 1987 ACR criteria.
- • Definite bony erosions in at least one affected sibling.
- • Age of disease onset greater than 18 years and less than 60 years in at least one sibling.
- • Neither sibling has psoriasis, inflammatory bowel disease, or systemic lupus erythematosus.
- BLOOD RELATIVES OF AFFECTED SIBLING PAIRS:
- • Age greater than 18 years.
- • Where possible, all other affected siblings will be invited to participate.
- • Where possible, both parents of affected siblings will be invited to participate.
- • Other relatives, both affected and unaffected, may be invited to participate if, in the opinion of the investigators, samples from these individuals would contribute important genetic information. Two cases in which this might happen are: a) extended families in which there are several affected individuals, where conventional linkage analysis might be applied; b) affected sibling pairs for which parents are unavailable, where additional siblings will provide information on parental alleles not transmitted to the affected siblings.
- EXCLUSION CRITERIA FOR AFFECTED SIBLINGS:
- • Psoriasis, inflammatory bowel disease, systemic lupus erythematosus.
- • Inability to provide infomed consent.
- • The sole criterion for exclusion of adult blood relatives of affected sibling pairs would be inability to provide informed consent.
Trial Officials
Daniel L Kastner, M.D.
Principal Investigator
National Human Genome Research Institute (NHGRI)
About National Institute Of Arthritis And Musculoskeletal And Skin Diseases (Niams)
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) is a pivotal component of the National Institutes of Health (NIH) dedicated to advancing research and knowledge in the fields of arthritis, musculoskeletal disorders, and skin diseases. NIAMS sponsors a wide range of clinical trials aimed at improving the diagnosis, treatment, and prevention of these conditions. By fostering innovative research, collaborating with healthcare professionals, and engaging with patient communities, NIAMS strives to enhance the quality of life for individuals affected by these diseases, while promoting scientific discovery and public health initiatives.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bethesda, Maryland, United States
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0
Similar Trials